Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | Abstract | ||||||||||||
| PMID | |||||||||||||
| Authors | Jun Zhou, Jiajia Yuan, Lan Zhang, Qing Zhu, Ming Yang, Hao Chen, Weimin Ding, Xielin Feng, Kui Wang, Yueyin Pan, Shanzhi Gu, Yanru Qin, Weiwei Kong, Qi Xu, Zengqing Guo, Hong Zhao, Yujia Zhu, Caixia Sun, Jean Fan, and Lin Shen | ||||||||||||
| Title | Tinengotinib (TT-00420) in advanced/metastatic FGFR2-altered cholangiocarcinoma following prior chemotherapy and FGFR inhibitor treatment: Results from a phase II study (FIRST-08). | ||||||||||||
|
|||||||||||||
| URL | https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.4133 | ||||||||||||
| Abstract Text | Background: Subsequent treatment options for advanced cholangiocarcinoma (CCA) after failure of chemotherapy and FGFR inhibitors (FGFRi) are limited. Tinengotinib (TT-00420), a novel FGFRi, potently inhibited FGFR2 fusion/rearrangement and acquired resistant/FGFR2 kinase domain mutations. The FIRST-08 study is an open-label, multicenter Phase II study in Chinese patients (pts) with advanced/metastatic CCA (NCT06057571). Methods: Eligible pts with advanced/metastatic CCA harboring FGFR2 fusion or arrangement, who had failed prior chemotherapy and one FGFRi, received tinengotinib 10 mg orally once daily in 21-day cycles. The primary endpoint was objective response rate (ORR) per RECIST v1.1 by blinded independent central review (BICR). Secondary endpoints included progression free survival (PFS), disease control rate (DCR), duration of response (DoR), overall survival (OS), safety, PK and quality of life (QOL) per EORTC QLQ-C30. Results: As of June 27, 2025, 50 pts were enrolled (median age 56.5 years; 52.0% male; ECOG of 1: 44.0%). Median follow-up was 8.5 months. Forty percent had ≥ 3 prior systemic regimens, 66.0% had prior immunotherapy, and 42.0% had received other targeted therapies beyond FGFRi. The ORR by BICR was 28.0% (95%CI, 17.5~41.7) with 14 confirmed partial responses, and median DoR was 7.9 (5.6~ -) months. The disease control rate (DCR) was 82.0%. The median PFS was 5.7 (4.3~8.3) months. The median OS had not reached, with the 18 months survival rate 66.9% (47.3~80.6). Common Gr3/4 TRAEs (≥15%) included hypertension (42.0%), palmar-plantar erythrodysesthesia syndrome (16.0%), No Gr 5 TRAE was observed. 41 out of 50 pts had biomarker ctDNA samples collected at baseline, 82.9% pts had FGFR2 fusion and 48.8% had FGFR2 mutation (SNV). 28 pts had biomarker ctDNA samples collected at both baseline and C3D1. A significant decrease in maximum variant allele frequencies (MaxVAF) from baseline to C3D1 by a median relative VAF reduction of 83.7% (p<0.0001), indicating strong molecular response to tinengotinib. Conclusions: Tinengotinib demonstrated durable clinical anti-tumor activity and a manageable safety profile in heavily pretreated CCA pts with FGFR2 fusion/rearrangement following prior chemotherapy and FGFRi therapy. Clinical trial information: NCT06057571. | ||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 rearrange | cholangiocarcinoma | predicted - sensitive | Tinengotinib | Phase II | Actionable | In a Phase II trial (FIRST-08), treatment with Tinengotinib (TT-00420) resulted in an objective response rate of 28.0% (14/50, all partial responses), median duration of response of 7.9 months, disease control rate of 82.0%, median progression-free survival of 5.7 months, median overall survival not reached, and 18-month survival rate of 66.9% in patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement (J Clin Oncol 2026 44:16_Suppl, 4133; NCT06057571). | detail... |